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Abstract: Most reported studies with animal models of abdominal aortic aneurysm (AAA) 
and several studies with patients have suggested that doxycycline favourably modifies  
AAA; however, a recent large long-term clinical trial found that doxycycline did not  
limit aneurysm growth. Thus, there is currently no convincing evidence that doxycycline 
reduces AAA expansion. Here, we critically review the available experimental and clinical 
information about the effects of doxycycline when used as a pharmacological treatment for 
AAA. The view that AAA can be considered an autoimmune disease and the observation 
that AAA tissue shows clonal expansion of T cells is placed in the light of the well-known 
inhibition of mitochondrial protein synthesis by doxycycline. In T cell leukaemia  
animal models, this inhibitory effect of the antibiotic has been shown to impede T cell 
proliferation, resulting in complete tumour eradication. We suggest that the available 
evidence of doxycycline action on AAA is erroneously ascribed to its inhibition of matrix 
metalloproteinases (MMPs) by competitive binding of the zinc ion co-factor. Although 
competitive binding may explain the inhibition of proteolytic activity, it does not explain the 
observed decreases of MMP mRNA levels. We propose that the observed effects of 
doxycycline are secondary to inhibition of mitochondrial protein synthesis. Provided that 
serum doxycycline levels are kept at adequate levels, the inhibition will result in a 
proliferation arrest, especially of clonally expanding T cells. This, in turn, leads to the 
decrease of proinflammatory cytokines that are normally generated by these cells. The 
drastic change in cell type composition may explain the changes in MMP mRNA and protein 
levels in the tissue samples. 
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1. Introduction 
Abdominal aortic aneurysm (AAA) is characterised by a progressive localised weakening and 
dilatation of the abdominal aorta. AAA is a common and serious medical condition in elderly people, 
especially among men [1]. The 2013/2014 results of the National Health Service AAA Screening 
Programme suggested a 1.25% prevalence of AAA with a diameter larger than 3.0 cm in 65-year-old 
men who had not had previous AAA surgery [2]. There is a high propensity to rupture when the 
aneurysm diameter reaches 5.0 to 5.5 cm. The mortality associated with AAA rupture is about 70% [2,3]; 
the majority of patients will die before they reach the operating theatre due to massive internal bleeding. 
Small aneurysms are, however, not void of the risk of rupture either [4]. 
Surgical repair is currently the only available treatment option for AAA. There are two scenarios for 
surgical intervention: traditional open repair and endovascular repair [5–7]. Small, asymptomatic AAAs 
are normally managed conservatively by regular monitoring. Current guidelines recommend surgical 
repair when the aneurysm diameter is expanding by more than 1 cm per year or is larger than 5.5 cm. 
Nevertheless, conservative management may remain the preferred choice for patients at high risk of 
mortality during surgical treatment. 
2. Pharmacological Interventions for AAA 
A pharmacological treatment that arrests or slows the progression of AAAs, thus reducing the 
pressure for surgical intervention, would have major advantages for patients as well as the healthcare 
system. Various drug targets have been considered and numerous attempts to affect these targets have 
been reported. An overview of these studies is given in Table 1. The advances in mechanistic studies 
that provide insights into these potential pharmacological treatments of AAA have been reviewed 
recently [8–10]. The authors conclude that, to date, there is no proven pharmacological intervention 
available for preventing the expansion and rupture of AAA. The observation reported recently that 
aneurysmal lesions contain clonally expanded T cells [11] prompted us to compare the available 
evidence for the reported inhibitory effects of doxycycline on AAA with our own experiences in tumour 
systems [12,13]. 
3. Doxycycline and AAA 
In its initial stage, AAA is an inflammatory condition. Roles for B and T lymphocytes have long  
been recognised in AAA disease [14–16]. This has led to the notion that AAA may be a specific  
antigen-driven T cell disease [17,18] and attempts to characterise the antigens have been published [19].  
In a recent review, treatment with the tetracycline antibiotic doxycycline was advocated as a non-invasive 
therapy for AAA, based on its inhibitory effects on matrix metalloproteinases (MMPs) [10]. A moderate 
change of MMP activity was confirmed in a clinical trial by Lindeman et al. [20] but their main 
observation concerned a significant reduction of the aortic wall neutrophil and cytotoxic T cell content. 
Int. J. Mol. Sci. 2015, 16 11180 
 
 
The recent finding by Lu et al. [11] that aneurysmal lesions contain clonally expanded T cells  
may indicate that Lindeman et al. [20] have actually observed the inhibitory effect of doxycycline on 
this expansion. 
Table 1. Targets and pharmacological approaches for a conservative treatment of abdominal 
aortic aneurysm (AAA). 
Targets Pharmacological Approaches References 
Neutrophils and other blood components 
Anti-neutrophil antibodies,  
TNF-α inhibition, mycophenolate [21–28] this review 
β-Adrenergic blockade Propranolol [29–33] 
Renin-angiotensin system TGF-β1, cyclosporine A [22,24,28,34–47] 
Cholesterol metabolism Various statins and proteases [43,47–57] 
Phospholipid metabolism 
5-LO inhibitors, cyclooxygenase-2 
inhibitors, EP4 inhibitors 
[26,28,58–64] 
Peroxisome proliferation-associated  
receptor (PPAR) 
Glitazones [65,66] 
Various proteases: cysteine proteases,  
serine proteases, matrix metalloproteinases 
(MMPs), elastase and others 
Calpain inhibitors, chymase 
inhibitors, doxycycline, 
azithromycin, rhoxithromycin 
[24,25,33,39,41,67–70] 
this review 
4. Doxycycline and Inhibition of T Cell Clonal Expansion 
Mitochondria, which are descendants of α-proteobacteria, are sensitive to antibacterial agents 
interfering with ribosomal function, such as doxycycline [71]. Our extensive in vitro and in vivo 
investigations on the cytostatic and cytocidic effects of doxycycline and some other tetracycline 
antibiotics, led us to the idea that inhibition of mitochondrial protein synthesis and the subsequent 
decrease of the mitochondrial energy-generating capacity is a key target to fight cancer [13].  
Tumour growth can be defined as a form of clonal expansion. In a rat T cell leukaemia model, arrest of 
T cell proliferation through inhibition of mitochondrial protein synthesis by doxycycline has been 
demonstrated to lead to a total elimination of the tumour [72,73]. It is tempting to speculate that 
inhibition of mitochondrial protein synthesis is the primary effect of doxycycline in the experimental 
and clinical studies of AAA. The proposed mechanism is illustrated in Figure 1. 
5. Doxycycline and Inhibition of Matrix Metalloproteinases (MMPs) 
MMPs play a key role in the degradation of extracellular matrix in normal physiological processes, 
such as embryonic development and tissue remodelling, as well as in pathogenic mechanisms of, e.g., 
tumour metastasis, arthritis and the formation of AAA [74]. Most members of the MMP family are 
soluble enzymes, secreted as inactive proproteins, which are activated upon cleavage by extracellular 
proteinases. A subset of MMPs however, is anchored to the plasma membrane. One of the most widely 
studied membrane-type MMPs, MT1-MMP, participates in the turnover of various extracellular matrix 
components and the activation of secreted MMPs [75]. MT1-MMP was reported to have an important 
function in the macrophage-dependent destruction of the elastin fibre network during AAA formation [76]. 
The secreted MMP-2 (gelatinase A) and MMP-9 (gelatinase B) participate in the catalytic cleavage of 
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extracellular gelatine and collagen. In addition, MMP-9 may also exert non-catalytic anti-apoptotic 
signalling effects [77]. Both MMP-2 and -9 are thought to be directly involved in AAA formation. 
 
Figure 1. Schematic presentation of the possible causes of clonal expansion of T cells and 
the inhibition of doxycycline. 
Tetracyclines are known to inhibit the activity of MMPs. This action has been attributed to their 
competitive binding of the catalytic zinc ion needed for MMP activity. Various natural tetracyclines  
and synthetic analogues have been tested as MMP inhibitors [78,79]. The aim of these studies was 
inhibition of the breakdown of the extracellular matrix that is thought to promote AAA formation and  
to facilitate metastasis of tumour cells [80]. The mechanism of action of MMP inhibition has been  
a rationale to design and produce tetracycline analogues void of antibacterial activity [78,81–83].  
The fact that the exclusion of this activity might also cause loss of antimitochondrial activity has not 
been tested or has even been considered [78,83]. Non-antibacterial tetracycline analogues have been 
tested in a number of human cancer trials [84]. Unfortunately, so far, these studies yielded mostly 
disappointing results [78,79] and their poor clinical performances as anticancer agents have been  
stressed [85]. Curci et al. examined a series of 15 patients with AAA, of whom 8 patients were treated 
with an oral dose of 100 mg of doxycycline twice a day for 7 days prior to surgery [86]. Total MMP 
enzyme activity measurements in post-operative aneurysm tissue failed to show differences. 
6. Doxycycline in Cell Culture and Animal Models of AAA 
Table 2 summarises the main aspects of the studies in which doxycycline has been tested as a possible 
drug in experimental animal models of AAA. The daily oral or subcutaneous dosage of doxycycline 
used in the in vivo studies varies from 10 to 100 mg/kg. The current dosage for patients in standard 
doxycycline treatment is approximately 1.5 or 3 mg/kg; however, not the dosage is critical but the serum 
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levels that are reached. These are, unfortunately, lacking in most studies. Only Prall et al. showed that 
their regimes for humans and mice gave comparable blood levels [87]. 
Doxycycline has been shown to effectively inhibit AAA formation in most reported animal studies 
(Table 2; [88]). Furthermore, a delay of aneurysm rupture by doxycycline has been demonstrated in  
a mouse model of Marfan syndrome, a genetic connective tissue disorder [89]. These effects have  
been ascribed to a reduction of MMP-9 activity with a preservation of elastin in the extracellular  
matrix [90]. In cultured THP-1 monocytes, stimulated with phorbol ester, decreased expression of  
MMP-9 mRNA and proprotein have been observed after doxycycline treatment [86]. Even so, in their 
review of 2008, Baxter et al. concluded that additional studies are needed to clarify the role of 
doxycycline in the progression of aneurysmal disease [8]. 
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Table 2. Effect of doxycycline in studies of AAA animal models. 
Publication Doxycycline 
No. of Animals 
Study Parameters 
Effect 1st Author 
(Year) 
Ref. Dosage Serum Level Type Duration Methods Outcomes 
Petrinec, D.  
(1996) 
[90] 12.5 mg bid, s.c. No data 48 rats PC ≤14 days el.-ind. AAA MMP exp.;  
MMP act.; expansion 
+ 
Boyle, J.R.  
(1998) 
[91] 1 and 10 µg/mL NA 8 porcine samples In vitro 13 days el.-ind. AAA MMP exp.; MMP act + 
Curci, J.A.  
(1998) 
[92] n.s., s.c. No data 52 rats Open controlled 7 days el.-ind. AAA 
MMP exp.;  
MMP act.; expansion 
+ 
Prall, A.K.  
(2002) 
[87] 
10, 50, 100 mg/kg/d  
in d.w. 
1.4, 2.7,  
11.9 µg/mL 
n.s. (mice) Open PC 10 weeks el.-ind. AAA MMP exp.; expansion + 
Manning, M.W. 
(2003) 
[93] 30 mg/kg/d in d.w. No data 
60 mice 
(hyperlipidemic) 
PC 5 weeks ang. II-ind. AAA Expansion + 
Sho, E.  
(2004) 
[94] 
60 mg/kg/d, s.c.;  
1.5 mg/kg/d via infusion 
No data n.s. (rats) PC Controlled 14 days 
el.-ind. AAA;  
periaortic infusion 
MMP exp.; expansion; 
macrophage density 
+ 
Bartoli, M.A.  
(2006) 
[95] 
100 mg/kg/d  
systemic p.o. 
0.33 µg/mL n.s. (mice) Open comparative 14 days el.-ind. AAA Expansion + 
≤1 mg/kg/d via  
local infusion 
5.6‒7.8 ng/mL n.s. (mice) Open comparative 14 days 
el.-ind. AAA;  
localised infusion with 
osmotic minipump 
Expansion + 
Xiong, W.  
(2008) 
[89] 100 mg/kg/d in d.w. No data 48 mice Open PC 
6 weeks +  
follow-up 
Marfan syndrome Survival + 
Xie, X. (2012) [96] 100 mg/kg/d in d.w. 2.3 ± 0.6 μg/mL 25 mice PC 8 weeks ang. II-ind. AAA Expansion – 
Sivaraman, B.  
(2013) 
[97] 
2%, 5% and 10%  
in nanoparticles 
NA 
n.s.  
(rat AAA tissue) 
In vitro 
Rats: 2 weeks 
TC: 3 weeks 
el.-ind. AAA MMP exp.; MMP act + 
Abbreviations: ang. II-ind. AAA, angioptensin II-induced AAA; bid, twice daily; d.w., drinking water; el.-ind. AAA, elastase-induced AAA; MMP exp., MMP gene 
expression; MMP act, MMP enzyme activity; NA, not applicable; n.s., not specified; PC, placebo-controlled; p.o., oral; s.c., subcutaneous; TC, tissue culture. 
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Improved efficacy on juxta-aortic delivery of doxycycline has been shown in rats by Sho et al. with 
the aid of a novel prototype infusion system [94]. To avoid dose-related side effects of systemic 
administration of doxycycline, localised administration with osmotic mini-pumps has been applied in 
mice by Bartoli et al. [95]. In their experiments, the doxycycline level in aortic tissue was extremely  
low as compared to those in other studies. Despite of the low concentration, the authors claimed that the 
localised administration suppressed aortic dilatation. The development of doxycycline formulations  
with nanoparticles may offer another approach for localised, controlled and sustained release in the  
future [97]. 
As mentioned above, MMP-9 may prevent apoptosis in a non-catalytic manner [77]. This deserves 
further attention since apoptosis would have a healing effect on AAA. Induction of apoptosis by 
tetracyclines has been reported [98]. In this context, an in vivo investigation with doxycycline in mice 
bearing an experimentally induced AAA should be mentioned [87]. In this study, doxycycline serum 
levels were measured after 5 weeks of treatment. The levels matched those obtained with standard doses 
in patients (2 to 9 μg/mL of serum) and are within the range of an antimitochondrial effect [13]. Although 
a decrease in aortic diameter and expression of active MMP-9 and its proprotein were shown following 
doxycycline treatment, the authors did not investigate an antimitochondrial effect and this can, therefore, 
not be excluded as the primary cause of the aneurysm growth inhibition. 
While in most animal studies doxycycline was administered prior to the initiation of the disease,  
Xie et al. [96] started administration in mice 28 days after induction of AAA. This scenario may be more 
relevant to patients, where a treatment for established AAA is needed. During the 8 weeks of treatment, 
expansion rates of AAAs were not reduced, suggesting that doxycycline is not effective in this mouse 
model of established AAA [96]. 
7. Doxycycline in Clinical Trials of AAA Patients 
Table 3 sums up the results of investigations in patients. In most studies, a fixed oral dose of 100 mg 
twice daily was used. In the oldest study, published in 1999 [99], tissue from five patients treated with 
doxycycline was compared with that from five untreated patients. MMP-2 and -9 mRNA levels in 
aneurysmal tissue obtained at the time of surgery were strongly reduced by preoperative treatment  
as compared to the untreated disease controls. Although the study of 15 patients by Curci et al. [86], 
mentioned in paragraph 5, failed to show differences in MMP-9 enzyme activity, doxycycline-treated 
patients did show reduced levels of MMP-9 mRNA and protein, as well as a suppressed modification of 
MMP-2 proprotein in macrophages. Promising results were also obtained in a prospective, double-blind, 
placebo-controlled pilot study with 32 patients by Morosin et al. [100]. The active group received oral 
doses of 150 mg of doxycycline daily for a period of 3 months. The aneurysm expansion rate in the 
active group was significantly lower than that in the placebo group. In a similar-sized prospective, 
double-blind, placebo-controlled, phase-II, multicentre study, no significant change was seen in the 
aneurysm expansion rate but prolonged administration of doxycycline was associated with a gradual 
reduction in plasma MMP-9 levels; however, enzyme activities were not measured [101]. 
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Table 3. Effect of doxycycline in clinical trials with AAA patients. 
Publication Doxycycline  Study Parameters  
1st Author  
(Year) 
Ref. Dosage Serum Level 
No. of  
Patients 
Type Duration Outcomes Effect 
Thompson, R.W. 
(1999) 
[99] 100 mg 2× dd No data 10 Open 7 days Small AAA + 
Curci, J.A.  
(2000) 
[86] 100 mg 2× dd No data 15 
Open 
controlled 
7 days MMP exp. + 
Mosorin, M.  
(2001) 
[100] 150 mg 1× dd No data 32 DBPC 
3 months  
+15 months 
Expansion, 15 months 
surveillance 
+ 
Baxter, B.T.  
(2002) 
[101] 100 mg 2× dd 4.62 µg/mL 36 
DBPC 
Phase II 
6 months MMP exp.; expansion +; − 
Prall, A.K.  
(2002) 
[87] 100 mg 2× dd 1.8–9.2 µg/mL n.s. Open 6 months 
Serum levels in range of those 
of mice in comparative study 
(see Table 2) 
+ 
Brown, D.L.  
(2004) 
[102] 20 mg 2× dd No data 50 DBPC 6 months 
Acute coronary  
syndromes, MMP exp. 
No AAA 
Hackmann, A.E. 
(2008) 
[68] 100 mg 2× dd No data 44 DBPC 6 months MMP exp.; expansion +; + 
Lindeman, J.H.N. 
(2009) 
[20] 
50, 100, 300 mg  
1× dd 
No data 60 
SB 
controlled 
2 weeks 
MMP exp.; MMP act; 
leukocyte content 
+; ±; + 
Meijer, C.A.  
(2013) 
[103] 100 mg 1× dd No data 286 DBPC 18 months Expansion − 
Kurosawa, K. 
(2013) 
[10,104] 100 mg 2× dd No data 248 DBPC 
2–3 years 
(planned) 
Study in progress unkown 
Abbreviations: 1× dd, once daily; 2× dd, twice daily; DBPC, double-blind placebo-controlled; MMP act., MMP enzyme activity; MMP exp., MMP gene expression;  
n.s., not specified; SB, single (investigator) blinded. 
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Although the study does not concern AAA but acute coronary syndromes, it is interesting to mention 
the paper by Brown et al., who performed a prospective, double-blind, placebo-controlled pilot study of 
50 patients, in which the active group was treated with an oral dose of 20 mg of doxycycline twice daily 
for a period of 6 months [102]. This relatively low dose, described as “subantimicrobial dose” [105], 
was chosen to exclude an effect on Chlamydia pneumoniae that otherwise might have interfered with 
the primary experimental goal. Pro-MMP-9 activity, but not MMP-2 activity, was decreased after  
6 months [102]. Unfortunately, no data were included on the course and level of doxycycline in serum. 
For in vivo experiments it is important to check if the dose used is not only subantimicrobial but also 
“subantimitochondrial”. In view of the half-life of doxycycline in humans, a cumulative effect remains 
conceivable [106]. It might well be that 20 or 50 mg twice daily gives a result comparable with 100 mg 
twice daily; the latter dose is acceptable however, based on experience with the treatment of bacterial 
infections and in some of the studies cited here. A serum level between 2 and 5 µg/mL, the range of  
the antimitochondrial action [13], can certainly be reached at a dose of 20 mg twice daily, assuming  
a half-life of 18 h [107]. 
Hackmann et al. [68] carried out a double-blind, placebo-controlled trial of 44 patients after 
endoluminal aneurysm repair. After 6 months of treatment with placebo or 100 mg of doxycycline twice 
daily, plasma MMP-9 levels were decreased significantly below baseline in the doxycycline group, while 
there was a non-significant increase in the placebo group. Moreover, based on the endograft used, 
doxycycline treatment resulted in greater reductions in maximum aortic diameter than placebo treatment. 
Recently a trial assessing the efficacy of 100 mg doxycycline daily in 286 patients with small AAAs 
was reported [103]. This study included approximately 8 times the number of patients involved in previous 
small positive trials (Table 3). The investigators reported no benefit of doxycycline administered at this 
dose over 18 months; in fact, AAA growth was significantly greater in patients randomised to the active 
agent [103]. The dose of doxycycline used in this recent trial was less than in a number of previous 
investigations [86,99–101]. The dose of doxycycline chosen was based on a previous investigation in 
which the drug was assessed in 60 patients with large AAAs awaiting open aortic surgery [20].  
That study suggested that 100 mg of doxycycline daily markedly reduced inflammation within the AAAs 
of patients randomised to the medication. The drug administration period was very short however at  
2 weeks. It is conceivable that a single daily oral dose of 100 mg of doxycycline is not sufficient to 
maintain adequate doxycycline serum levels for a prolonged period [108]. If the doxycycline serum levels 
drop too low during the day, then the suggested benefits of the drug outlined in this article may not be 
able to be realised. A large on-going trial is investigating the benefit of a larger daily dose of doxycycline 
in patients with small AAAs [10,104]. Overall however there is currently no convincing clinical data 
that doxycycline benefits patients with small AAAs. 
8. Direct and Indirect Effects of Doxycycline 
The question was raised recently if any of the pharmacological agents tested do really slow the 
progression of AAA [61]. Lu et al. conclude that there remain many undefined complexities regarding  
the mechanisms and their possible translational consequences in spite of an improved understanding [9].  
As discussed in this review, several studies support doxycycline treatment of patients with pre-operative 
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AAA or at high risk of mortality at surgical intervention; however, we strongly question the assumption 
that clinical improvement with doxycycline can be ascribed to direct inhibition of the expression of MMPs. 
Although the ability of doxycycline to chelate zinc may explain the effect on MMP enzyme activity 
and, possibly, MMP protein levels through destabilisation of its structure, there is no explanation how 
doxycycline can have an effect on the MMP mRNA levels. Therefore, we postulate that the primary 
effect of doxycycline is based on its inhibition of mitochondrial protein synthesis, preventing clonal 
expansion of T-cells and possibly also other proliferating cells in AAA tissue, thus, indirectly, resulting 
in a decrease of proinflammatory cytokines, MMP-2 and MMP-9 that otherwise damage the vascular 
stroma [9,28,41]. Whilst there is no direct experimental evidence available that the observed effects of 
doxycycline on AAA are based on its inhibition of mitochondrial protein synthesis, the finding of  
Lu et al. [11] that aneurysmal lesions contain clonally expanded T cells combined with our own 
observations in cancer research that doxycycline results in a proliferation arrests of T cells through its 
inhibition of mitochondrial protein synthesis [72,73] lends strong support to our hypothesis. The resulting 
changes in cell type composition of the AAA tissue render quantification of mRNA and primary 
translation products unreliable. Hence, the measured effects of doxycycline on MMP expression are 
indirect because the antibiotic does not influence nuclear-cytosolic protein synthesis. 
We hope that this critical review and our new hypothesis on the role of doxycycline as drug of choice 
in AAA will spur further research on the possible role of mitochondrial protein inhibition in the treatment 
of AAA. Although the recent, large, double-blind, placebo-controlled Dutch clinical trial found that a 
single daily dose of 100 mg of doxycycline did not reduce aneurysm growth [103], we believe that 
further investigations are justified. A vital demand for success is a permanent serum level of doxycycline 
at a concentration that effectively inhibits mitochondrial protein synthesis; twice a day a moderate dose 
may suffice. Such a treatment scenario (100 mg twice daily), or even a higher dosage (200 mg twice 
daily), is regularly applied to patients with Lyme disease [109–111]. Measurement of peak wall stress 
may be a useful parameter to judge a significant contribution of doxycycline to a better prognosis for 
AAA [3]. A large on-going clinical trial with a doxycycline dose of 100 mg twice daily, estimated to be 
completed June 2017, has been announced [10]. Surveillance of serum levels is, unfortunately, not 
included as secondary outcome [104]. 
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